ATE320488T1 - Mutanten des lag-3 proteins, ihre expression und verwendung - Google Patents

Mutanten des lag-3 proteins, ihre expression und verwendung

Info

Publication number
ATE320488T1
ATE320488T1 AT97947136T AT97947136T ATE320488T1 AT E320488 T1 ATE320488 T1 AT E320488T1 AT 97947136 T AT97947136 T AT 97947136T AT 97947136 T AT97947136 T AT 97947136T AT E320488 T1 ATE320488 T1 AT E320488T1
Authority
AT
Austria
Prior art keywords
protein
lag
mutants
expression
fragments
Prior art date
Application number
AT97947136T
Other languages
English (en)
Inventor
Tayar Nabil El
Renato Mastrangeli
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE320488T1 publication Critical patent/ATE320488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97947136T 1996-11-28 1997-11-25 Mutanten des lag-3 proteins, ihre expression und verwendung ATE320488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614608 1996-11-28

Publications (1)

Publication Number Publication Date
ATE320488T1 true ATE320488T1 (de) 2006-04-15

Family

ID=9498133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947136T ATE320488T1 (de) 1996-11-28 1997-11-25 Mutanten des lag-3 proteins, ihre expression und verwendung

Country Status (9)

Country Link
US (1) US6482925B1 (de)
EP (1) EP0942973B1 (de)
JP (1) JP2000516101A (de)
AT (1) ATE320488T1 (de)
AU (1) AU728911B2 (de)
CA (1) CA2273080C (de)
DE (1) DE69735502T2 (de)
IL (1) IL130123A (de)
WO (1) WO1998023741A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596871A4 (de) 2003-02-28 2006-08-23 Drew M Pardoll T-zell-regulierung
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
KR100808925B1 (ko) 2006-09-29 2008-03-03 고려대학교 산학협력단 돼지 ｌａｇ-3 융합 이뮤노글로블린
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BR112013033661A2 (pt) 2011-06-30 2017-01-24 Genzyme Corp inibidores de ativação de células t
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3508502B1 (de) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Kombination aus anti-lag-3-antikörpern und anti-pd-1-antikörpern zur behandlung von tumoren
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3660050A1 (de) 2014-03-14 2020-06-03 Novartis AG Antikörpermoleküle gegen lag-3 und verwendungen davon
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
EP3399989B1 (de) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3-antikörper und antigenbindende fragmente
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178306C2 (ru) * 1994-05-06 2002-01-20 Энститю Гюстав Русси Растворимые полипептидные фракции протеина lag-3, способ получения, терапевтическая композиция, антитело

Also Published As

Publication number Publication date
EP0942973A1 (de) 1999-09-22
AU728911B2 (en) 2001-01-18
CA2273080A1 (fr) 1998-06-04
CA2273080C (fr) 2004-11-09
DE69735502T2 (de) 2006-12-14
EP0942973B1 (de) 2006-03-15
AU5229498A (en) 1998-06-22
WO1998023741A1 (fr) 1998-06-04
US6482925B1 (en) 2002-11-19
JP2000516101A (ja) 2000-12-05
IL130123A (en) 2007-07-24
IL130123A0 (en) 2000-06-01
DE69735502D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
ATE335078T1 (de) Überexpression von säugetier- und virusproteinen
DE68916512D1 (de) Zusammensetzung zur Verminderung von postoperativen Adhäsionen und ihre Verwendung.
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
DE69635452D1 (de) Hohe expressionsrate des grün-fluoreszierenden proteins
DE69732881D1 (de) Verwendung von zusammensetzungen mit stabilisierten enzymen
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
NO971875L (no) Cathepsin 02 protease
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
EP0209543A4 (de) Peptidfragmente menschlicher apolipoproteine, typspezifische antikörper und verwendungsverfahren.
DE69111768D1 (de) Enzymatische Zusammensetzung zur Bestimmung von Äthanol.
DK1012186T3 (da) Keratinocyt-vækstfaktorer og anvendelser deraf
WO2000017328A3 (en) Fibrils
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DE3786616D1 (de) Bacillus brevis-staemme und ihre verwendung.
DK0942992T3 (da) O-fucosyltransferase
DE69535337D1 (de) Transkriptionsfaktor e2f-5
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties